Cellular and T cell engager Immunotherapy
Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated Analysis
Eric M. Jurgens, MD
Fellow, Hematology and Medical Oncology
Department of Medicine, Memorial Sloan Kettering Cancer Center, United States